



Press release

MiP Pharma (Homburg/Saar): Extension of the Homburg site completed - sale of the site ensures long-term expansion under new ownership - focus on sales of own pharmaceuticals to accelerate growth

Homburg, May 13, 2025. MiP Pharma Group has successfully completed the expansion of its production site in Homburg and sold the facility to the internationally active Famar Group. The Famar Group, a renowned global pharmaceutical CDMO (Contract Development and Manufacturing Organization), will integrate the site into its worldwide production network and further develop it. This sale ensures the long-term future of the site while MiP Pharma shifts its focus to the marketing of its own pharmaceutical products.

Over the past two years, MiP Pharma has made significant investments to expand the facility. These efforts, strongly supported by majority shareholder capiton, included new packaging lines, additional laboratory capacities, and extensive technical upgrades.

As part of the acquisition, approximately 100 employees will transfer to the new owner, who plans to further develop the site in the long term. The handover is expected to be completed in the coming months. For MiP Pharma, this step is part of a clear strategy to focus more on the marketing of its own pharmaceutical products and to strengthen collaborations with leading European production partners.

Dr. Friedrich Sernetz, CEO of MiP Pharma, highlighted the strategic importance of the sale: "Thanks to the investments, the Homburg facility has become an attractive site for global pharmaceutical specialists. With the Famar Group, we have found a buyer who will not only maintain but also further develop the site. This secures jobs and lays the foundation for future growth. At the same time, we can focus on our core competency – the marketing of our medicines – and accelerate our growth."

Alexander Zamora, Partner at capiton, added: "We are proud to have supported the expansion of the Homburg facility. The sale to the Famar Group strengthens the site and creates a solid foundation for MiP Pharma's future growth."

The Famar Group, a leading provider in the field of contract development and manufacturing of pharmaceuticals, sees great potential in Homburg. "The Homburg facility offers us the opportunity to expand our business with international clients. We look forward to working with the highly skilled local workforce and to further developing the site," said Konstantinos Rengis, CEO of the Famar Group. He also emphasized the importance of the partnership with MiP Pharma: "This collaboration is a significant milestone in advancing the development and manufacturing of medicines in Europe together."

About MiP Pharma Group

The MiP Pharma Group markets prescription generics, primarily antibiotics, over-the-counter medicines and medical devices. The main markets are Germany and Poland as well as some other Eastern European markets. The sales focus is on the hospital business and addressing selected specialist groups. With over 200 employees and around 400 marketing authorisations, MiP Pharma generated sales of around 50 million euros in the last financial year. Since November 2020, the



previously family-run MiP Pharma has been a portfolio company of the Berlin-based financial investor capiton AG.

About Famar Group

FAMAR is a leading European provider of pharmaceutical and cosmetic manufacturing and development services. With a legacy of 75 years of technology expertise, FAMAR delivers high-quality dosage forms, including sterile liquids, solids, and semi-solids, creating value for its clients. Operating in Spain, Italy, and Greece, employing over 1,850 people across a network of six production facilities and two R&D centers, FAMAR supplies a wide range of more than 1,700 different products for over 80 international markets. For more information, please visit the official FAMAR website at <https://www.famar-group.com>.